Acerus Receives Notice of Deficiency – Withdrawal Letter from Health Canada Regarding Gynoflor Application

Pharmaceutical Investing

Acerus Pharmaceuticals (TSX:ASP) is today advising that it has received a Notice of Deficiency-Withdrawal Letter for its Gynoflor New Drug Submission. As quoted in the press release: “We are disappointed with the Health Canada decision on GynoflorTM,” said Ed Gudaitis, President and CEO of Acerus Pharmaceuticals. “GynoflorTM is currently approved in over 40 countries across Europe, Asia, …

Acerus Pharmaceuticals (TSX:ASP) is today advising that it has received a Notice of Deficiency-Withdrawal Letter for its GynoflorNew Drug Submission.

As quoted in the press release:

“We are disappointed with the Health Canada decision on Gynoflor^TM,” said Ed Gudaitis, President and CEO of Acerus Pharmaceuticals. “Gynoflor^TM is currently approved in over 40 countries across Europe, Asia, the Middle East, Africa and South America and we are understandably surprised that we could not obtain approval in Canada. We will study the details of the Notice and work with Medinova AG, the manufacturer and licensor of Gynoflor^TM, to assess our next steps.”

Click here to read the full press release.

acerus pharmaceuticals health canada tsx:asp Company News